logo
The Role Of Quality Engineering In Safeguarding Medical Decisions

The Role Of Quality Engineering In Safeguarding Medical Decisions

Forbes24-07-2025
Gopinath Kathiresan is a veteran QE leader combining AI, cybersecurity and automation to build smarter, secure software.
AI is transforming healthcare, from interpreting scans to powering early warning systems that guide diagnosis and treatment. In fact, according to a 2024 McKinsey survey, around 70% of healthcare organizations are now using or planning to use generative AI.
But AI is not without risk. Earlier in my career, I worked at GE Healthcare and Bio-Rad Laboratories, where I saw how small software issues could carry clinical consequences. One misfire in device communication or a delayed result in a diagnostic tool could mean a missed treatment window.
That's why, in healthcare, quality doesn't just mean good code. It means protecting patients in real-world, high-stakes moments.
Why Healthcare AI Needs A New Kind Of Oversight
AI in healthcare is advancing fast. Models now help detect tumors, predict readmissions, flag deteriorating patients and assist with triage decisions. A 2023 study in Lancet Digital Health even found that AI-based diagnostic tools, such as those for skin cancer detection, can sometimes match or outperform specialists, especially novice specialists.
But performance in a controlled environment doesn't always translate to the chaos of real-world hospitals.
We can't assume an algorithm is 'good enough' just because it clears a data scientist's benchmark. We need to engineer for safety from the start. That means moving beyond static accuracy numbers and thinking deeply about how AI performs under pressure, across patient types and in unpredictable situations.
The Limitations Of Traditional QA In Medical AI
Earlier in my career as a quality engineer, I worked on regulated diagnostic software and medical device platforms. I contributed to test automation for verification workflows, validated device communication and ensured clinical accuracy standards were met.
That hands-on experience shaped how I think about risk, reliability and patient safety in software and the importance of quality engineering (QE) in healthcare.
Healthcare organizations have long practiced software testing. But testing AI is a different beast. AI models behave probabilistically. They're trained on datasets that might not reflect the populations they serve. Their outputs evolve as conditions shift.
A tool that performs with 95% accuracy in one hospital might drop dramatically in another, due to differences in demographics, calibrations or data quality. In fact, research has shown that rural hospitals or hospitals with fewer resources, for example, may buy AI tools off-the-shelf, meaning the data the AI is trained on looks different than their hospital's population, which can impact performance.
This is where QE must step in, not just as a checkpoint, but as a design partner focused on:
• Bias detection across patient populations.
• Edge-case testing for rare or high-risk conditions.
• Explainability validation to ensure clinicians can interpret results.
• Monitoring for model drift after deployment.
Quality engineers aren't just testing systems; they're safeguarding patients.
From Bugs To Bias: What A Modern QE Pipeline Looks Like
The FDA has acknowledged this new frontier, and its updates to its software as a medical device (SaMD) guidelines show that the agency is acknowledging both AI's potential and risk. While its guidance isn't finalized, they are focusing on several aspects of how AI can impact medical devices, including ongoing monitoring and performance validation for AI and machine learning tools.
But real-world safety demands more than checkboxes. It requires QE practices that validate AI performance not only at launch but also throughout its lifecycle. So what does 'clinical-grade' QE look like in practice? Emerging best practices include:
• Scenario-Based Test Automation: QE teams should consider how these tools will work in real-world scenarios. For example, researchers at the SIMNOVA Simulation Center developed an AI workflow to create and test realistic healthcare simulation scenarios.
• Synthetic Data Injection: Synthetic data can help to round out data samples during testing. For example, Stanford's RoentGen project improved classifier accuracy using synthetic chest X-rays.
• Demographic Audit Layers: Mainly because of the data it's trained on, AI can perform differently based on factors like a patient's ethnicity or gender, emphasizing the importance of fairness audits
• Collaborative Validation: Subject matter experts, such as clinicians and other healthcare stakeholders, should be included in the AI design process to ensure that issues that impact the real-world use of these tools are considered.
This shift isn't just a technical evolution; it's foundational to trust in healthcare AI.
AI Won't Replace Testers—It'll Make Their Role Even More Critical
There's a common fear that AI might make testers obsolete. In healthcare, the opposite is true. AI may help automate test generation and monitor systems post-deployment, but human quality engineers bring what AI can't: context, curiosity and caution. Humans should ask:
• 'Would this still work in an emergency room?'
• 'Is the model unintentionally learning the wrong patterns?'
• 'Could this mislead a busy nurse under pressure?'
That kind of judgment is forged from hands-on experience. No AI system, no matter how advanced, can replace the human instinct to ask, 'What could go wrong here?' If you're in healthcare tech, this is a call to action:
• Testers: Learn AI model behavior and where quality gaps emerge.
• Developers: Collaborate with QE teams early during integration.
• Leaders: Treat quality as foundational, not a bolt-on.
What matters most isn't what AI can do in theory, but how it behaves when seconds count, when a nurse or physician is making a call that could save a life.
The Role Quality Must Play In Saving Lives
Software doesn't just support healthcare anymore; it is healthcare. And as AI becomes more central to decisions, QE must evolve from assurance to active defense.
I've spent over 15 years working in software quality, including time in regulated healthcare. I've seen how fragile trust becomes when tools fail, and how powerful it is when teams get it right. Now more than ever, we need QE professionals to be the silent guardians of patient safety, testing not just for bugs, but for bias, breakdowns and blind spots.
Because when AI enters the hospital, the question isn't just 'Does it work?' It's about whether it will protect the patient when it truly counts.
Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hyperscience Recognized on the 2025 Inc. 5000 List of Fastest-Growing Private Companies in America
Hyperscience Recognized on the 2025 Inc. 5000 List of Fastest-Growing Private Companies in America

Yahoo

time23 minutes ago

  • Yahoo

Hyperscience Recognized on the 2025 Inc. 5000 List of Fastest-Growing Private Companies in America

Groundbreaking AI and ML models and explosive demand for its Intelligent Document Processing platform across public and private sectors propel the company forward NEW YORK, August 12, 2025--(BUSINESS WIRE)--Hyperscience, a market leader in hyperautomation and a provider of enterprise AI infrastructure software, today announced its inclusion on the prestigious 2025 Inc. 5000 list of America's fastest-growing private companies. The company's proven success in delivering operational efficiencies across numerous verticals has earned it a spot on the list for the first time. This placement comes on the heels of a breakout year marked by the release of the company's Optical Reasoning and Cognition Agent (ORCA), its next-generation Vision-Language Model (VLM), and rapid adoption of its platform across government agencies, global enterprises, and regulated industries. "Being recognized on the Inc. 5000 list for the first time reflects the years of hard work and commitment of our teams, and is a testament to our achievements in leading the charge for intelligent automation," said Andrew Joiner, CEO of Hyperscience. "At Hyperscience, we're not just building AI, we're reshaping how the world works with information. This placement reinforces our mission to deliver AI that understands, empowers, and accelerates outcomes for organizations everywhere." Hyperscience transforms organizations everywhere with a turnkey AI platform that accelerates the processing of documents and forms that flow through an enterprise's back office. Designed with a "human-in-the-loop" approach, this platform leverages the strengths of both humans and machines. Hyperscience comprehensively manages data from input to extraction, orchestrating end-to-end processes. With industry-leading accuracy (99.5 percent) and automation (98 percent), Hyperscience automates tedious tasks, enabling workforces to spend their time on higher-level projects. The Inc. 5000 list, compiled annually by Inc. magazine, ranks the 5000 fastest-growing private companies in the United States based on revenue growth over the past three years. Making the Inc. 5000 is a significant achievement that places Hyperscience among the most dynamic and successful businesses in the country. For the full list, company profiles, and a searchable database by industry and location, visit: About Hyperscience Hyperscience is a market leader in hyperautomation and a provider of enterprise AI infrastructure software. The Hyperscience Hypercell platform unlocks the value of an organization's back office data through the automation of end-to-end processes, and transforms complex documents into LLM and RAG-ready data to power new enterprise GenAI experiences. This enables organizations to transform manual, siloed processes into a strategic advantage, resulting in a faster path to decisions, actions, and revenue; positive and engaging customer, public, and patient experiences; and dramatic increases in productivity. Leading organizations across the globe rely on Hyperscience to drive their hyperautomation initiatives, including American Express, Charles Schwab, HM Revenue and Customs, Mars, Stryker, The United States Social Security Administration, and The United States Department of Veterans Affairs. The company is funded by top tier investors including Bessemer Venture Partners, Battery, FirstMark, Stripes, and Tiger Global. View source version on Contacts Media Jyotsna (415) 917-7411 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

AI Startup, Perplexity Wants to Buy Chrome Browser for $34.5B
AI Startup, Perplexity Wants to Buy Chrome Browser for $34.5B

Yahoo

time23 minutes ago

  • Yahoo

AI Startup, Perplexity Wants to Buy Chrome Browser for $34.5B

AI startup Perplexity has made an unsolicited proposal to purchase Google's Chrome browser for $34.5 billion in cash, according to a company spokesperson. The bid comes after growing regulatory pressure on Google, with a federal judge previously ruling that the company holds an illegal monopoly in internet search. The U.S. government may require Google to sell Chrome and share its search data with competitors. Perplexity, valued at $18 billion after a funding round earlier this year, says multiple large investment funds have agreed to fully finance the purchase. The company has also been working on its own, newly released but still only available via invites, AI-powered browser, Comet, which has integrated AI agent capabilities. The proposal includes a pledge to invest $3 billion over the next two years to improve Chrome and its open-source base, Chromium. Perplexity says It would extend job offers to a large portion of the existing Chrome team. Has promised not to make hidden changes to the browser. Google Search would remain the default search engine under Perplexity's ownership, and the code would stay open-source. Google is unlikely to voluntarily part with Chrome, as it plays a central role in the company's search and AI plans. Some industry experts value Chrome at over $50 billion, which could mean Perplexity's offer is lower than what Google might accept, as reported by Bloomberg. Other companies, including OpenAI, have also shown interest in acquiring Chrome should authorities force its sale. Any such deal would have a big impact on how billions of people access the web.

Trump Floats Deal to Let Nvidia's Blackwell Chips Into China -- With a 50% Power Cut
Trump Floats Deal to Let Nvidia's Blackwell Chips Into China -- With a 50% Power Cut

Yahoo

time23 minutes ago

  • Yahoo

Trump Floats Deal to Let Nvidia's Blackwell Chips Into China -- With a 50% Power Cut

President Donald Trump has signaled he may be open to letting Nvidia (NASDAQ:NVDA) ship a toned-down version of its most advanced Blackwell AI chip to China if the company trims its capabilities by 30% to 50%. The comment comes shortly after Trump confirmed an unusual arrangement already in place for Nvidia's less-powerful H20 chip, which allows exports to China in exchange for a 15% revenue share paid directly to the US government. Advanced Micro Devices will follow the same formula for its MI308 chip, according to a person familiar with the matter. Nvidia has not commented on the president's remarks. Warning! GuruFocus has detected 5 Warning Signs with NVDA. The potential deal for Blackwell would mirror Trump's broader push to secure financial returns for the US in exchange for loosening certain export restrictions a strategy that could influence how American companies negotiate market access in China. While Trump didn't outline a specific timeline, he suggested Nvidia CEO Jensen Huang could soon meet with him to discuss a negatively enhanced Blackwell variant. If approved, the move could mark a shift in how high-end US chip technology is selectively offered abroad. Nvidia's Blackwell chips are the backbone of today's most powerful AI systems but remain off-limits to China under current US rules. Both Nvidia and AMD (NASDAQ:AMD) have taken revenue hits as tighter controls limited exports to older models on par with domestic Chinese alternatives products that have struggled to gain traction. Nvidia has already said it is developing another China-specific chip and will seek approval to sell it. The company noted that further cutting back its Hopper-based H20 chip is no longer viable, suggesting a modified Blackwell could be the clearest path to regaining momentum in one of the world's largest AI markets. This article first appeared on GuruFocus. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store